Halyard Health Inc. (NYSE:HYH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
A number of other research firms have also weighed in on HYH. Deutsche Bank AG lifted their price objective on Halyard Health from $36.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, August 10th. TheStreet upgraded Halyard Health from a “sell” rating to a “hold” rating in a research report on Friday, July 8th. Finally, Stifel Nicolaus raised their target price on Halyard Health from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, August 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $34.20.
Halyard Health (NYSE:HYH) traded down 1.59% on Tuesday, hitting $33.99. The stock had a trading volume of 519,426 shares. The firm’s market cap is $1.59 billion. Halyard Health has a 52-week low of $22.76 and a 52-week high of $37.31. The company has a 50-day moving average price of $35.11 and a 200 day moving average price of $32.79.
Halyard Health (NYSE:HYH) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.09. The business earned $400 million during the quarter, compared to analyst estimates of $383.08 million. Halyard Health had a positive return on equity of 8.91% and a negative net margin of 27.63%. The company’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the business posted $0.52 EPS. Equities analysts forecast that Halyard Health will post $1.82 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in Halyard Health by 204.2% in the second quarter. Nisa Investment Advisors LLC now owns 14,897 shares of the company’s stock valued at $484,000 after buying an additional 10,000 shares during the last quarter. Gateway Investment Advisers LLC purchased a new stake in Halyard Health during the second quarter valued at about $439,000. BNP Paribas Arbitrage SA boosted its stake in Halyard Health by 799.0% in the second quarter. BNP Paribas Arbitrage SA now owns 28,740 shares of the company’s stock valued at $935,000 after buying an additional 25,543 shares during the last quarter. Springbok Capital Management LLC boosted its stake in Halyard Health by 151.9% in the first quarter. Springbok Capital Management LLC now owns 6,800 shares of the company’s stock valued at $195,000 after buying an additional 4,100 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in Halyard Health by 22.2% in the first quarter. Nuveen Asset Management LLC now owns 85,044 shares of the company’s stock valued at $2,443,000 after buying an additional 15,467 shares during the last quarter. Institutional investors own 82.93% of the company’s stock.
Halyard Health Company Profile
Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.